These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2692652)

  • 1. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems.
    Ebbs SR; Saunders JA; Graham H; A'Hern RP; Bates T; Baum M
    Acta Oncol; 1989; 28(6):887-92. PubMed ID: 2692652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Høst H
    Eur J Cancer; 1990 Jan; 26(1):45-8. PubMed ID: 2138477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Chen SC; Chang HK; Lin YC; Cheung YC; Tsai CS; Leung WM; Hsueh S; Chen MF
    Onkologie; 2005 Jun; 28(6-7):339-44. PubMed ID: 15933422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
    Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
    Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
    Gregory RK; Johnston SR; Smith IE; Miles D
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):47-9. PubMed ID: 11098493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
    Rischin D; Smith J; Millward M; Lewis C; Boyer M; Richardson G; Toner G; Gurney H; McKendrick J
    Br J Cancer; 2000 Aug; 83(4):438-42. PubMed ID: 10945487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
    de Matteis A; Nuzzo F; D'Aiuto G; Labonia V; Landi G; Rossi E; Mastro AA; Botti G; De Maio E; Perrone F
    Cancer; 2002 Feb; 94(4):895-901. PubMed ID: 11920456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A weekly schedule of epirubicin in pretreated advanced breast cancer.
    Barni S; Archili C; Lissoni P; Paolorossi F; Crispino S; Tancini G
    Tumori; 1993 Feb; 79(1):45-8. PubMed ID: 8497922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.
    Habeshaw T; Paul J; Jones R; Stallard S; Stewart M; Kaye SB; Soukop M; Symonds RP; Reed NS; Rankin EM
    J Clin Oncol; 1991 Feb; 9(2):295-304. PubMed ID: 1988576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
    Wishart GC; Bissett D; Paul J; Jodrell D; Harnett A; Habeshaw T; Kerr DJ; Macham MA; Soukop M; Leonard RC
    J Clin Oncol; 1994 Sep; 12(9):1771-7. PubMed ID: 8083699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.
    Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
    Acta Oncol; 1992; 31(2):231-6. PubMed ID: 1622639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
    Yayoi E; Furukawa J; Takatsuka Y; Kobayashi T; Aikawa T; Maeura Y; Kaji M; Kotsuma Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1621-4. PubMed ID: 1530320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.